title: Orthostasis as a test for cerebral autoregulation in normal persons and patients with carotid artery disease.
abstract: Orthostasis reduces mean flow velocity (FVmean) in cerebral arteries. This might be used as an alternative provocation test for cerebral hemodynamics in patients with carotid artery disease (CAD). In 21 unilateral CAD patients and 21 controls, FVmean in both middle cerebral arteries (MCA) was measured by transcranial Doppler, together with blood pressure (BP) and heart rate (HR) during a tilt table test. Cerebrovascular reserve (CVR) was measured by an acetazolamide test. In all cases, FVmean dropped to a lower level (controls: 81.9 +/- 9.4% of baseline; patients: 84.3 +/- 7.9% symptomatic side, 85.6 +/- 9.0% contralateral). Impaired CVR patients showed a smaller (p < 0.01) decrease (90.6 +/- 3.3%) compared to contralateral (84.9 +/- 6.0%), to normal CVR patients (81.1 +/- 7.8%) and to controls. Heart rate increased in both groups (controls: +16.6 +/- 9.9%, patients +10.3 +/- 9.9%; p < 0.01); BP showed no change. Orthostasis induces a decrease of MCA FVmean as already previously described. This decrease is significantly smaller in patients with impaired CVR. Since BP does not change, some authors explain the lower MCA Fvmean during orthostasis as caused by sympathetic induced vasoconstriction of cerebral resistance vessels. The authors speculate that in impaired CVR-patients autoregulative protection against ischemia might limit vasoconstriction. In combination with standard tests for measurement of CVR, this test might be useful for evaluation of cerebral autoregulation.
authors: Department of Neurology, Saarland University, Homburg, Germany.
authors: M
authors: M
authors: Stoll
authors: A
authors: A
authors: Seidel
authors: K
authors: K
authors: Schimrigk
authors: G F
authors: GF
authors: Hamann
mesh_terms: D000086:Acetazolamide; D001783:Blood Flow Velocity / Q000187:drug effects / Q000502:physiology; D001794:Blood Pressure / Q000502:physiology; D002545:Brain Ischemia / Q000503:physiopathology; D002257:Carbonic Anhydrase Inhibitors; D002340:Carotid Artery Diseases / Q000000981:diagnostic imaging / Q000503:physiopathology*; D002536:Cerebral Arteries / Q000000981:diagnostic imaging / Q000502:physiology; D002560:Cerebrovascular Circulation / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006706:Homeostasis / Q000502:physiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011187:Posture / Q000502:physiology*; D013564:Sympathetic Nervous System / Q000502:physiology; D018667:Tilt-Table Test; D017585:Ultrasonography, Doppler, Transcranial; D014655:Vascular Resistance / Q000502:physiology; D014661:Vasoconstriction / Q000502:physiology
chemical_list: D002257:Carbonic Anhydrase Inhibitors; D000086:Acetazolamide